Laboratorios Richmond net profit more than doubled to AR$ 13.92 billion in 1H FY26; net sales fall 16.68% to AR$ 63.49 billion

Reuters2026/08/06 18:16

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Laboratorios Richmond posted attributable net profit of AR$ 13.94 billion for the first half, swinging from profit of AR$ 4.52 billion a year earlier.
Net sales fell 16.68% to AR$ 63.49 billion, reflecting a temporary demand contraction and a shift in public-sector purchasing timing.
Operating income dropped 91.55% to AR$ 1.11 billion, weighed by AR$ 8.02 billion in unabsorbed fixed manufacturing costs during the VIDA plant ramp-up.
Net financial result swung to a gain of AR$ 15.06 billion from a loss of AR$ 7.72 billion, driven by inflation of 16.85% versus 2% peso depreciation.
The VIDA plant began initial vaccine sales in March, while the company cited a US$ 5.6 million public-sector purchase order covering 1,600,000 doses over 12 months.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Laboratorios Richmond SACIF published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Laboratorios Richmond net profit more than doubled to AR$ 13.92 billion in 1H FY26; net sales fall 16.68% to AR$ 63.49 billion

You may also like

Crypto prices